Merger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise
August 10, 2021
Cancer patients have been heavily impacted by the ongoing COVID-19 pandemic. With thousands of tissue biopsies delayed and patients postponing clinic visits across Canada, increasing access to circulating tumour DNA (ctDNA) testing for targeted treatment selection has offered another option for oncologists.
November 19, 2020
In this presentation, Dr. Gregory Tranah, of Sutter Health, discusses opportunities and challenges that bringing in-house testing to a large, complex, health system presents. Dr. Tranah will discuss critical success factors for others who are considering embarking on this path.
November 6, 2020
An international panel discuss their experience and insights on maintaining high levels of care for cancer patients, in the midst of a global pandemic, as well as their perspectives on how care may be transformed in the long-term.
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.